Studies have confirmed that immune site inhibitors can enhance the anti‐tumor activity of immune cells by blocking the programmed cell death protein 1(PD‐1) pathway, and combining chemotherapy with immune checkpoint inhibitors (ICIs) is gradually becoming the preferred option for the treatment of various cancers.7, 8. The gene discussed is PDCD1; the disease is neoplasm.